New insider activity at Chemed ( (CHE) ) has taken place on September 29, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
President and CEO Kevin J. McNamara has recently sold 3,000 shares of Chemed stock, amounting to a total transaction value of $1,383,840.
Recent Updates on CHE stock
In the past 24 hours, Chemed’s stock has experienced notable developments. BofA lowered its price target for Chemed due to concerns about a potentially negative policy and reimbursement environment, despite solid hospital fundamentals. Meanwhile, Jefferies upgraded Chemed to a Buy rating, citing better-than-expected fiscal 2026 reimbursement rates, particularly in Florida, which could position the company for high-end EBITDA performance. Additionally, aggressive share buybacks are expected to drive the stock’s multiple higher. Oppenheimer also adjusted its price target downward, reflecting a cautious outlook. These changes reflect a mixed sentiment driven by external policy factors and internal financial strategies.
Spark’s Take on CHE Stock
According to Spark, TipRanks’ AI Analyst, CHE is a Outperform.
Chemed’s overall stock score reflects strong financial performance and moderate technical indicators. While the company maintains a solid financial position, challenges highlighted in the earnings call, such as reduced earnings guidance and specific operational issues, impact the score. The valuation suggests the stock is fairly priced, but the modest dividend yield limits its appeal to income-focused investors.
To see Spark’s full report on CHE stock, click here.
More about Chemed
YTD Price Performance: -12.48%
Average Trading Volume: 189,536
Technical Sentiment Signal: Sell
Current Market Cap: $6.74B